Stock Research: Adaptive Biotechnologies

Independent stock analysis through peer comparison: Get the 360° View as an objective basis for stock decision-making and explore the detailed ranks.

Adaptive Biotechnologies

NSQ:ADPT US00650F1093
49
  • Value
    53
  • Growth
    33
  • Safety
    Safety
    73
  • Combined
    49
  • Sentiment
    59
  • 360° View
    360° View
    49
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

Adaptive Biotechnologies Corporation is a biotechnology company focused on harnessing the adaptive immune system for disease diagnosis and treatment. It operates in the fields of Minimal Residual Disease (MRD) with its clonoSEQ clinical diagnostic test, and Immune Medicine, discovering and developing immune-based therapies for cancer and autoimmune diseases. In the last fiscal year, the company had 619 employees, a market cap of $1701 million, profits of $107 million, and revenue of $179 million.

more
Index
NASDAQ
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 27-Feb-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
53 6 55 25
Growth
33 99 71 29
Safety
Safety
73 8 98 87
Sentiment
59 80 57 47
360° View
360° View
49 47 94 21
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
33 64 67 42
Opinions Change
50 28 50 50
Pro Holdings
n/a 82 39 83
Market Pulse
100 75 49 26
Sentiment
59 80 57 47
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
53 6 55 25
Growth
33 99 71 29
Safety Safety
73 8 98 87
Combined
49 19 94 56
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
68 39 59 17
Price vs. Earnings (P/E)
100 60 60 10
Price vs. Book (P/B)
18 4 60 55
Dividend Yield
1 1 1 1
Value
53 6 55 25
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
44 91 88 70
Profit Growth
38 60 61 28
Capital Growth
20 88 58 70
Stock Returns
73 95 21 9
Growth
33 99 71 29
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
15 30 100 100
Refinancing
89 23 75 49
Liquidity
78 28 26 n/a
Safety Safety
73 8 98 87

Similar Stocks

Discover high‑ranked alternatives to Adaptive Biotechnologies and broaden your portfolio horizons.

Global Payments

NYQ:GPN
Country: USA
Industry: Other Financial Services
Size: X-Large
Full Stock Analysis

Omnicom

NYQ:OMC
Country: USA
Industry: Advertising
Size: X-Large
Full Stock Analysis

Mosaic

NYQ:MOS
Country: USA
Industry: Fertilizers & Agricultural Chemicals
Size: X-Large
Full Stock Analysis

Labcorp

NYQ:LH
Country: USA
Industry: Health Care Services
Size: X-Large
Full Stock Analysis

Frequently Asked
Questions

This is a classic, high-risk growth play: high growth and positive sentiment outweigh low Value Rank (expensive) and risky financing. This is for aggressive growth investors who are comfortable with the high price and risk, believing the growth story justifies the expense.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing: